Cargando…

Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling

Natural killer (NK) cells are innate effector lymphocytes with strong antitumor effects against hematologic malignancies such as chronic lymphocytic leukemia (CLL). However, NK cells fail to control CLL progression on the long term. For effective lysis of their targets, NK cells use a specific cell-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurzer, Hannah, Filali, Liza, Hoffmann, Céline, Krecke, Max, Biolato, Andrea Michela, Mastio, Jérôme, De Wilde, Sigrid, François, Jean Hugues, Largeot, Anne, Berchem, Guy, Paggetti, Jérôme, Moussay, Etienne, Thomas, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181408/
https://www.ncbi.nlm.nih.gov/pubmed/34108958
http://dx.doi.org/10.3389/fimmu.2021.619069
_version_ 1783704089680412672
author Wurzer, Hannah
Filali, Liza
Hoffmann, Céline
Krecke, Max
Biolato, Andrea Michela
Mastio, Jérôme
De Wilde, Sigrid
François, Jean Hugues
Largeot, Anne
Berchem, Guy
Paggetti, Jérôme
Moussay, Etienne
Thomas, Clément
author_facet Wurzer, Hannah
Filali, Liza
Hoffmann, Céline
Krecke, Max
Biolato, Andrea Michela
Mastio, Jérôme
De Wilde, Sigrid
François, Jean Hugues
Largeot, Anne
Berchem, Guy
Paggetti, Jérôme
Moussay, Etienne
Thomas, Clément
author_sort Wurzer, Hannah
collection PubMed
description Natural killer (NK) cells are innate effector lymphocytes with strong antitumor effects against hematologic malignancies such as chronic lymphocytic leukemia (CLL). However, NK cells fail to control CLL progression on the long term. For effective lysis of their targets, NK cells use a specific cell-cell interface, known as the immunological synapse (IS), whose assembly and effector function critically rely on dynamic cytoskeletal changes in NK cells. Here we explored the role of CLL cell actin cytoskeleton during NK cell attack. We found that CLL cells can undergo fast actin cytoskeleton remodeling which is characterized by a NK cell contact-induced accumulation of actin filaments at the IS. Such polarization of the actin cytoskeleton was strongly associated with resistance against NK cell-mediated cytotoxicity and reduced amounts of the cell-death inducing molecule granzyme B in target CLL cells. Selective pharmacological targeting of the key actin regulator Cdc42 abrogated the capacity of CLL cells to reorganize their actin cytoskeleton during NK cell attack, increased levels of transferred granzyme B and restored CLL cell susceptibility to NK cell cytotoxicity. This resistance mechanism was confirmed in primary CLL cells from patients. In addition, pharmacological inhibition of actin dynamics in combination with blocking antibodies increased conjugation frequency and improved CLL cell elimination by NK cells. Together our results highlight the critical role of CLL cell actin cytoskeleton in driving resistance against NK cell cytotoxicity and provide new potential therapeutic point of intervention to target CLL immune escape.
format Online
Article
Text
id pubmed-8181408
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81814082021-06-08 Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling Wurzer, Hannah Filali, Liza Hoffmann, Céline Krecke, Max Biolato, Andrea Michela Mastio, Jérôme De Wilde, Sigrid François, Jean Hugues Largeot, Anne Berchem, Guy Paggetti, Jérôme Moussay, Etienne Thomas, Clément Front Immunol Immunology Natural killer (NK) cells are innate effector lymphocytes with strong antitumor effects against hematologic malignancies such as chronic lymphocytic leukemia (CLL). However, NK cells fail to control CLL progression on the long term. For effective lysis of their targets, NK cells use a specific cell-cell interface, known as the immunological synapse (IS), whose assembly and effector function critically rely on dynamic cytoskeletal changes in NK cells. Here we explored the role of CLL cell actin cytoskeleton during NK cell attack. We found that CLL cells can undergo fast actin cytoskeleton remodeling which is characterized by a NK cell contact-induced accumulation of actin filaments at the IS. Such polarization of the actin cytoskeleton was strongly associated with resistance against NK cell-mediated cytotoxicity and reduced amounts of the cell-death inducing molecule granzyme B in target CLL cells. Selective pharmacological targeting of the key actin regulator Cdc42 abrogated the capacity of CLL cells to reorganize their actin cytoskeleton during NK cell attack, increased levels of transferred granzyme B and restored CLL cell susceptibility to NK cell cytotoxicity. This resistance mechanism was confirmed in primary CLL cells from patients. In addition, pharmacological inhibition of actin dynamics in combination with blocking antibodies increased conjugation frequency and improved CLL cell elimination by NK cells. Together our results highlight the critical role of CLL cell actin cytoskeleton in driving resistance against NK cell cytotoxicity and provide new potential therapeutic point of intervention to target CLL immune escape. Frontiers Media S.A. 2021-05-24 /pmc/articles/PMC8181408/ /pubmed/34108958 http://dx.doi.org/10.3389/fimmu.2021.619069 Text en Copyright © 2021 Wurzer, Filali, Hoffmann, Krecke, Biolato, Mastio, De Wilde, François, Largeot, Berchem, Paggetti, Moussay and Thomas https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wurzer, Hannah
Filali, Liza
Hoffmann, Céline
Krecke, Max
Biolato, Andrea Michela
Mastio, Jérôme
De Wilde, Sigrid
François, Jean Hugues
Largeot, Anne
Berchem, Guy
Paggetti, Jérôme
Moussay, Etienne
Thomas, Clément
Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title_full Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title_fullStr Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title_full_unstemmed Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title_short Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling
title_sort intrinsic resistance of chronic lymphocytic leukemia cells to nk cell-mediated lysis can be overcome in vitro by pharmacological inhibition of cdc42-induced actin cytoskeleton remodeling
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181408/
https://www.ncbi.nlm.nih.gov/pubmed/34108958
http://dx.doi.org/10.3389/fimmu.2021.619069
work_keys_str_mv AT wurzerhannah intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT filaliliza intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT hoffmannceline intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT kreckemax intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT biolatoandreamichela intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT mastiojerome intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT dewildesigrid intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT francoisjeanhugues intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT largeotanne intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT berchemguy intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT paggettijerome intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT moussayetienne intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling
AT thomasclement intrinsicresistanceofchroniclymphocyticleukemiacellstonkcellmediatedlysiscanbeovercomeinvitrobypharmacologicalinhibitionofcdc42inducedactincytoskeletonremodeling